Apellis制药公司的股票在强劲的销售和大银行的投资刺激之后猛涨。 Apellis Pharmaceuticals' stock surged after strong sales and a big bank's investment boost.

Apellis制药公司的股份在星期二上升6.6%至22.36美元,市场上限为28.9亿美元。 Apellis Pharmaceuticals' shares rose 6.6% to $22.36 on Tuesday, reaching a market cap of $2.89 billion. 该公司的主要产品治疗自发免疫和发炎性疾病。 The company's main products treat autoimmune and inflammatory diseases. 加拿大国家银行FI大大增加了在Apellis的股权,在第四季度购买了1 385 080股,价值4 421万美元。 National Bank of Canada FI significantly increased its stake in Apellis, buying 1,385,080 shares in the fourth quarter, valuing their holdings at $44.21 million. Apellis 报告称，收入为 2.1250 亿美元，超出预期。 Apellis reported $212.50 million in revenue, beating expectations.